The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction-Reference-Cited by-同舟云学术

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction

Published:2020-10-23 Issue:11 Volume:20 Page:
ISSN:1534-4827
Container-title:Current Diabetes Reports
language:en
Short-container-title:Curr Diab Rep

Author:

Wang Xiaowen,Verma Subodh,Mason R. Preston,Bhatt Deepak L.

Abstract

Abstract Purpose of Review Epidemiological studies have long suggested the cardiovascular benefits of omega-3 fatty acids (OM3FAs). However, until recently, clinical trials using OM3FAs have been largely negative with respect to their cardioprotective effects. In this review, we aim to summarize key clinical trials, examine the clinical benefits of eicosapentaenoic acid (EPA) and potential mechanisms, and review the changes in guidelines and recommendations. Recent Findings The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) has demonstrated significant cardiovascular mortality benefits of purified EPA ethyl ester, with a 25% relative risk reduction in major cardiovascular events. Summary As first of its class to be approved, icosapent ethyl offers a new option to further reduce cardiovascular risks in patients already treated with maximally tolerated statins.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11892-020-01343-7.pdf

Reference83 articles.

1. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–41. https://doi.org/10.1056/NEJMoa1406656.

2. Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes. 2016;65(7):1767–78. https://doi.org/10.2337/db16-0046.

3. • Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330–43. https://doi.org/10.1016/j.jacc.2018.04.061. A review article that summarized the need to target hypertriglyceridemia to further reduce CV risk in high-risk individuals. It also summarized several ongoing trials at the time of the review, some of which have reported since then.

4. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation. 2003;107(14):1852–7. https://doi.org/10.1161/01.cir.0000062644.42133.5f.

5. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. 2004;109(22):2705–11. https://doi.org/10.1161/01.cir.0000132503.19410.6b.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficient Expression and Application of a Modified Rhizomucor miehei Lipase for Simultaneous Production of Biodiesel and Eicosapentaenoic Acid Ethyl Ester from Nannochloropsis Oil;Journal of Agricultural and Food Chemistry;2024-07-19

2. Omega-3 fatty acids and major depression: a Mendelian randomization study;Translational Psychiatry;2024-05-29

3. A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids;Cardiovascular Drugs and Therapy;2024-02-16

4. Omega-3 fatty acids for cardiovascular event lowering;European Journal of Preventive Cardiology;2024-01-03

5. Omega-3 Fatty Acids;Clinical Lipidology;2024